TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Phase 1b open-label study to evaluate the safety of selected TIL (TBio-4101) delivered after lymphodepleting chemotherapy and followed by intravenous (IV) bolus aldesleukin (IL-2) and pembrolizumab for patients with advanced HNSCC who have initially progressed on pembrolizumab or pembrolizumab/platinum chemotherapy.
Squamous Cell Carcinoma of Head and Neck|Metastatic Squamous Cell Carcinoma
BIOLOGICAL: TBio-4101|DRUG: Pembrolizumab|DRUG: Platinum based chemotherapy|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin
Safety and tolerability, The incidence of treatment-emergent adverse events will be tabulated using NCI CTCAE v5.0, Up to 2 years
Overall Response Rate (ORR), ORR will be determined using RECIST 1.1 and RECIST 1.1 for immune-based therapeutics (iRECIST)., Up to 5 years|Durable Response Rate (DRR), DRR, will be defined as a continuous CR or partial response (PR) beginning within 12 months of TBio-4101 treatment and lasting â‰¥ 6 months by RECIST 1.1 and iRECIST., Up to 5 years|Duration of Response (DoR), DoR will be determined using RECIST 1.1 and iRECIST., Up to 5 years|Disease Control Rate (DCR), DCR will be determined using RECIST 1.1 and iRECIST., Up to 5 years|Assess the feasibility of TBio-4101, Feasibility of TBio-4101 defined as the percentage of treated-patient population (TPP) patients over intent-to-treat (ITT)., Up to 5 years
Phase 1b open-label study to evaluate the safety of selected TIL (TBio-4101) delivered after lymphodepleting chemotherapy and followed by intravenous (IV) bolus aldesleukin (IL-2) and pembrolizumab for patients with advanced HNSCC who have initially progressed on pembrolizumab or pembrolizumab/platinum chemotherapy.